A laboratory data-based evaluation of the efficacy and safety of generic pravastatin sodium for long-term use

Masanori Suzuki1*, Motoyasu Kanamori2, Tomoaki Hashimoto2, Yuji Hashimoto3, Ryohkan Funakoshi1 and Tadanori Sasaki4

Abstract

Background: Increasing the use of generic drugs may reduce the growing healthcare spending. Nevertheless, in Japan, the generic drug market share remains low compared to that of European countries and the United States, mainly because of the general distrust of generic drugs. To address this problem, we retrospectively evaluated the efficacy and safety of the long-term use of generic pravastatin sodium in a study from January 2008 to December 2011.

Methods: Patients receiving generic pravastatin sodium for ≥15 months were defined as long-term users and were included in the study, totaling 595 out of 1337 patients. Efficacy assessment was based on the total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) plasma levels. Safety assessment was based on the aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase (CPK), gamma-glutamyl transferase (γ-GTP), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total-bilirubin (T-Bil), blood urea nitrogen (BUN), serum creatinine (Scr), and hemoglobin A1c (HbA1c) plasma levels. The patients’ reasons for discontinuing generic pravastatin sodium were obtained from the electronic medical records.

Results & discussion: No significant difference in the laboratory data was observed between short-term and long-term users, except for significantly lower ALT levels in the long-term users than in the short-term users. No liver dysfunction was observed. Although 37 patients discontinued the study possibly owing to drug-related adverse events, we considered these events unrelated to generic pravastatin sodium.

Conclusions: This study shows that the long-term use of generic pravastatin sodium is effective and safe, and may help dispel the concerns about generic drugs.

Keywords: Pravastatin sodium, Generic drugs, Long-term use

Background

Increasing the use of generic instead of branded drugs is desirable since it contributes to reducing healthcare spending [1]. Although the generic drugs’ penetration rates are approximately 50 % or more in Europe and the United States, according to an aggregated value based on a drug price survey conducted in September 2013, they are 46.9 % in Japan, and are currently still low [2, 3]. To address this situation, the Japanese Ministry of Health, Labour and Welfare has set a goal to increase the volume share of generic drugs to 60 % or more by the fiscal year of 2018. Promotion of the use of generics also plays a large role in the medical economy [4].

One of the reasons for the persistently low penetration rate of generic drugs is the distrust of doctors and patients because less information on their efficacy and safety is available than that for branded drugs [5]. To address this issue, it is important not only to ensure the biological and therapeutic equivalence of generic drugs to those of branded drugs, but also to clinically assess their efficacy and safety.

When we switched from branded to generic pravastatin sodium tablets at our hospital, we assessed the clinical efficacy and safety of the generic version on the
basis of laboratory data and reported our findings [6]. In this study, which included all 1337 patients who switched to the generic pravastatin sodium tablet Maibastan® (Towa Pharmaceutical, Co., Ltd.), we demonstrated that Maibastan’s clinical efficacy and safety were comparable to those of the branded Mevalotin® tablet (Daiichi Sankyo Co., Ltd.). However, since the study period was 6 months and the long-term use of Mevalotin® was defined as 15 months or longer [6], the impact of Maibastan’s long-term use on clinical efficacy and safety remains unknown. Moreover, although several clinical studies have compared and analyzed the efficacy and safety of branded and generic drugs in patients switching from branded to generic drugs, only few have investigated the clinical efficacy and safety of the long-term use of the latter [7–9]. Thus, in the present study, the duration of long-term use was defined as 15 months or longer [10], and the study period was extended to last from January 1, 2008 to December 31, 2011. All 1337 patients who had switched to Maibastan® in the previous study were followed up, and a retrospective observational study using information from electronic medical records to assess Maibastan’s long-term use clinical efficacy and safety was conducted.

Methods
Study period
From January 1, 2008, to December 31, 2011.

Design
Retrospective observational study.

Target patients
The present study included all 1337 patients who had switched from branded pravastatin sodium (Mevalotin® tablet) to a generic version (Maibastan® tablet) between January 1, 2008, and March 31, 2009. These patients were classified into 6 different groups: long-term continued use group, treatment discontinuation group (long-term), treatment discontinuation group (short-term), drug-change group, dose-adjustment group, and concomitant drug-change group (Fig. 1). Definition of the long-term treatment period was defined as 15 months or longer of treatment according to a clinical study on the long-term use of Mevalotin® [10].

Exclusion criteria
Patients for whom no efficacy and safety laboratory assessment data were obtained during the short- and long-term treatment periods were excluded from the study [5. Assessment items, 2]).

Assessment items

1) The number of the target patients, male-to-female ratio, mean age, and mean duration of orally administered Maibastan® tablets.

---

**Fig. 1** Overview of each treatment group and the study period. Short-term treatment period: From the day of substitution to March 31, 2009. Long-term treatment period: From July 1 to December 31, 2011. Long-term continued use group: Patients who continued the treatment on and after December 31, 2011. Treatment discontinuation group (long-term): Patients who discontinued the treatment between July 1 and December 31, 2011. Treatment discontinuation group (short-term): Patients who discontinued the treatment on or before July 1, 2011. Drug-change group: Patients for whom the generic drug was replaced by another drug after substitution. Dose-adjustment group: Patients for whom the dose of the generic drug was adjusted after substitution. Concomitant drug-change group: Patients whose concomitant drugs were switched after substitution. Long-term use group: A group consisting of the long-term continued use group and the treatment discontinuation group (long-term). Discontinuation/change group: A group consisting of the treatment discontinuation (short-term), drug-change, dose-adjustment, and concomitant drug-change group.
2) Efficacy and safety assessment based on laboratory data

- Efficacy assessment

In the long-term use group, the results of the first laboratory test during the short-term treatment period (from the day of substitution to March 31, 2009) were compared with the results of the latest laboratory test during the long-term treatment period (from July 1 to December 31, 2011) (Fig. 2). The efficacy of the long-term use of Maibastan® tablets was assessed by comparing the following laboratory data: total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C).

- Safety assessment

In the long-term use group, the results of the first laboratory test during the short-term treatment period (from the day of substitution to March 31, 2009) were compared with those of the last laboratory test during the long-term treatment period (from July 1 to December 31, 2011) (Fig. 2). The safety of Maibastan® tablets’ long-term use was assessed by comparing the following laboratory data: aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase (CPK), gamma-glutamyl transferase (γ-GTP), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total bilirubin (T-Bil), blood urea nitrogen (BUN), serum creatinine (Scr), and hemoglobin A1c (HbA1c).

3) Safety assessment based on the reasons for drug discontinuation and changes

To assess the safety of Maibastan®, we reviewed the medical records to identify the reasons underlying all Maibastan® discontinuation and replacement cases and compared the cases of adverse reactions to Maibastan® with those reported for Mevalotin®. In the event of adverse reactions that had not been reported for Mevalotin® or of death, the patient data were reviewed to investigate a causal relationship with orally administered Maibastan®.

The Common Terminology Criteria for Adverse Events version 4.0, Japan Clinical Oncology Group version (CTCAE, v4.0-JCOG), were used for grading of adverse reactions for the safety assessment.

Analytical methods

Student’s t-test was used for intergroup comparison of the laboratory data. The statistical significance level was set at $p < 0.05$.

The study protocol was approved by the Clinical Study Screening Committee at Kameda General Hospital.

Results

1) Sex and age of the target patients and treatment duration of orally administered Maibastan® tablets

Of the 1337 patients who had switched from Mevalotin® to Maibastan® tablets between January 1, 2008, and March 31, 2009, 595 patients continued receiving Maibastan® for approximately 177 weeks, whereas the remaining 742 patients discontinued or changed their treatment for undefined reasons. The long-term use group consisted of 556 and 39 patients in the long-term continued use and treatment discontinuation (long-term) group, respectively (Table 1). The discontinuation/change group consisted of 278, 329, 98, and 37 patients in the treatment discontinuation (short-term), drug-change, dose-adjustment, and concomitant drug-change group, respectively (Table 2). The efficacy and safety assessment based on laboratory data included the 595 patients in the long-term use group, while the safety assessment based on the reasons for discontinuation and drug change included 781 patients, i.e., 742 and 39 patients in the discontinuation/change and treatment discontinuation (long-term) group, respectively. No apparent difference was observed in the male-to-female ratio and mean age between the target patients.

2) Assessment of efficacy and safety based on laboratory data

- Efficacy assessment
In the long-term continued use group, no significant difference was observed in laboratory parameters between the Maibastan® tablets short- and long-term use groups (Table 3) and in those of the treatment discontinuation group (long-term) (Table 4).

Safety assessment

Although in the long-term continued use group, a significant decrease in ALT levels ($p = 0.02$) was observed between the short- and long-term use of Maibastan® tablets, no significant difference was observed in any of the other laboratory parameters (Table 3). Moreover, no significant difference in laboratory parameters was observed in the treatment discontinuation group (long-term) (Table 4).

3) Safety assessment based on the reasons for drug discontinuation and change

Among the 39 patients in the treatment discontinuation group (long-term), the reasons for discontinuation were not clearly indicated in the medical records of 28 patients. In five patients, treatment was discontinued because of transfer to another hospital and because of death, pregnancy, poor nutritional status, and advanced age preventing chronic treatment in 3, 1, 1, and 1 patient(s), respectively.

Among the 278 patients in the treatment discontinuation group (short-term), the reasons for discontinuation were not clearly indicated in the medical records of 141 patients. In 62 patients, treatment was discontinued because of transfer to another hospital, and in 33, 21, 13, 3, 3, and 2 patients, because of death, adverse reactions, decreased LDL-C levels, poor nutritional status, patient’s own request, and old age preventing chronic treatment, respectively. Among the 21 patients who discontinued treatment because of adverse reactions, eight patients presented symptoms suggestive of rhabdomyolysis, such as increased CPK levels and myalgia.

Among the 329 patients in the drug-change group, the reasons for drug change were not clearly indicated in the medical records of 187 patients. Maibastan® was replaced by other drugs because of poor LDL-C control in 116 patients (Crestor® [AstraZeneca, Inc.; 61 patients], Lipitor® [Astellas Pharma, Inc.; 54 patients], and Bezatol® [Kissei Pharmaceutical Co., Ltd.; 1 patient]) and because of poor TG control in 9 patients (Crestor®, Lipitor®, Bezatol®, and Lipidil® [Kaken Pharmaceutical Co., Ltd.; 2 patients each] and Zetia® [Bayer AG; 1 patient]). Moreover, 1 patient switched from Maibastan® to another drug (Bezatol®) because of favorable LDL-C control. Adverse reactions caused all 16 patients to switch from the generic drug to other drugs (Lipitor® tablet in 9 patients, Crestor® and Zetia® tablet in 3 patients each, and Epadel® capsule [Mochida Pharmaceutical Co., Ltd.] in 1 patient). Nine of the patients presented symptoms suggestive of rhabdomyolysis, such as increased CPK levels, myalgia, and weakness.

Among the 98 patients in the dose-adjustment group, the reasons for drug change were not clearly indicated in

| Table 1 Patient characteristics. (1) Long-term use group |
|-------------------------------------------------------|
| | Long-term continued use | Discontinuation (long-term) |
|------------------|--------------------------|
| Patients (N)     | 556                      | 39                       |
| Men/women (N)    | 224/332                  | 18/21                    |
| Mean age (years) | 68.8 ± 10.9              | 73.8 ± 11.8              |
| Mean treatment duration (weeks) | 177 ± 3.61 | 158 ± 3.54 |

| Table 2 Patient characteristics. (2) Discontinuation/change group |
|---------------------------------------------------------------|
| | Concomitant drug-change | Drug-change | Dose-adjustment | Discontinuation (short-term) |
|------------------|---------------|---------------|---------------------|
| Patients (N)     | 37            | 329           | 98                  | 278                 |
| Men/women (N)    | 24/13         | 150/179       | 44/54               | 103/175             |
| Mean age (years) | 66.7          | 66.8          | 68.1                | 70.9                |
| Mean treatment duration (weeks) | 144 ± 3.50 | 66.6 ± 3.53 | 143 ± 3.71 | 63.8 ± 4.00 |
| Age (years) Mean | S.D.          | Mean S.D.     | Duration (weeks) S.D. |                     |
| Long-term continued use | 68.8       | 10.9          | 177                 | 3.61                |
| Discontinuation (long-term) | 73.8       | 11.8          | 158                 | 3.54                |
| Concomitant drug-change | 66.7       | 11.0          | 144                 | 3.50                |
| Drug-change | 66.8          | 11.1          | 66.6                | 3.33                |
| Dose-adjustment | 68.1          | 11.2          | 143                 | 3.71                |
| Discontinuation (short-term) | 70.9       | 12.5          | 63.8                | 4.00                |

Standard deviation, S.D
the medical records of 33 patients. In 37 patients, the doses of Maibastan® tablet were reduced because of favorable LDL-C control, and in 27 and 1 patient(s), because of poor LDL-C and TG control, respectively.

Among the 37 patients in the concomitant drug-change group, the reasons for drug change were not clearly indicated in the medical records of 17 patients. In 11 patients, other drugs were added as treatment because of poor LDL-C control (Zetia® tablet in 10 patients and Bezatol® tablet in 1 patient) and poor TG control in 9 patients (Zetia® and Bezatol® tablet in 3 patients each, Lipidil® tablet in 2 patients, and Perycit® tablet [Sanwa Kagaku Kenkyusho Co., Ltd.] in 1 patient).

During the current study period, treatment was discontinued or changed because of adverse reactions in a total of 37 patients. Among them, abnormal laboratory

### Table 3 Assessment of efficacy and safety based on laboratory data (the long-term continual use group)

| Plasma parameter | Short-term treatment | Long-term treatment |
|------------------|----------------------|---------------------|
|                  | Mean ± S.D.          | N                   | Mean ± S.D. | N | p-value |
| TC               | 195 ± 25.0           | 407                 | 196 ± 28.5 | 417 | 0.42    |
| TG               | 129 ± 76.8           | 405                 | 123 ± 65.5 | 449 | 0.16    |
| HDL-C            | 608 ± 15.6           | 388                 | 61.9 ± 16.6| 437 | 0.32    |
| LDL-C            | 109 ± 20.1           | 239                 | 112 ± 24.0 | 246 | 0.06    |
| AST              | 24.2 ± 12.2          | 419                 | 23.2 ± 9.29| 473 | 0.19    |
| ALT              | 23.1 ± 21.6          | 418                 | 20.4 ± 11.3| 473 | 0.02    |
| CPK              | 112 ± 86.5           | 358                 | 108 ± 67.9 | 395 | 0.51    |
| γ-GTP            | 35.3 ± 52.4          | 324                 | 33.0 ± 35.5| 385 | 0.50    |
| ALP              | 236 ± 72.1           | 266                 | 245 ± 81.8 | 286 | 0.18    |
| T-Bil            | 0.66 ± 0.25          | 242                 | 0.67 ± 0.27| 303 | 0.91    |
| LDH              | 198 ± 37.4           | 372                 | 196 ± 39.1 | 417 | 0.48    |
| BUN              | 170 ± 8.78           | 384                 | 17.6 ± 8.39| 461 | 0.27    |
| Scr              | 0.87 ± 0.55          | 413                 | 0.91 ± 0.74| 478 | 0.40    |
| HbA1c            | 6.26 ± 0.83          | 308                 | 6.24 ± 0.88| 341 | 0.87    |

Total plasma cholesterol, TC; triglyceride, TG; high-density lipoprotein cholesterol, HDL-C; low-density lipoprotein cholesterol, LDL-C; aspartate aminotransferase, AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γ-GTP; alkaline phosphatase, ALP; lactate dehydrogenase, LDH; total bilirubin, T-Bil; blood urea nitrogen, BUN; serum creatinine, Scr; hemoglobin A1c, HbA1c; standard deviation, S.D

### Table 4 Assessment of efficacy and safety based on laboratory data (the treatment discontinuation group)

| Plasma parameter | Short-term treatment | Long-term treatment |
|------------------|----------------------|---------------------|
|                  | Mean ± S.D.          | N                   | Mean ± S.D. | N | p-value |
| TC               | 188 ± 31.2           | 31                  | 179 ± 39.4  | 16 | 0.38    |
| TG               | 117 ± 51.1           | 30                  | 109 ± 50.0  | 17 | 0.62    |
| HDL-C            | 61.4 ± 22.6          | 28                  | 59 ± 18.5   | 17 | 0.71    |
| LDL-C            | 102 ± 19.2           | 20                  | 96.6 ± 26.4 | 11 | 0.56    |
| AST              | 20.7 ± 7.15          | 33                  | 19.6 ± 7.29 | 26 | 0.57    |
| ALT              | 17.6 ± 9.37          | 33                  | 15.3 ± 7.74 | 26 | 0.32    |
| CPK              | 81.9 ± 40.1          | 30                  | 83.6 ± 44.1 | 19 | 0.89    |
| γ-GTP            | 31.7 ± 37.4          | 26                  | 39.1 ± 42.9 | 21 | 0.53    |
| ALP              | 237 ± 69.3           | 23                  | 285 ± 134  | 21 | 0.16    |
| T-Bil            | 0.76 ± 0.48          | 24                  | 0.57 ± 0.25 | 20 | 0.10    |
| LDH              | 190 ± 35.1           | 30                  | 182 ± 56.0  | 22 | 0.54    |
| BUN              | 16.6 ± 5.46          | 35                  | 19.3 ± 9.33 | 27 | 0.19    |
| Scr              | 0.85 ± 0.28          | 35                  | 0.91 ± 0.41 | 27 | 0.52    |
| HbA1c            | 6.32 ± 0.95          | 22                  | 6.15 ± 0.4  | 11 | 0.47    |

Total plasma cholesterol, TC; triglyceride, TG; high-density lipoprotein cholesterol, HDL-C; low-density lipoprotein cholesterol, LDL-C; aspartate aminotransferase, AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γ-GTP; alkaline phosphatase, ALP; lactate dehydrogenase, LDH; total bilirubin, T-Bil; blood urea nitrogen, BUN; serum creatinine, Scr; hemoglobin A1c, HbA1c; standard deviation, S.D
data were observed in 13 patients, and 24 patients re-
ported adverse reactions. The adverse reactions deter-
mved by abnormal laboratory data in the 13 patients
were increased CPK, AST and ALT, ALP and γ-GTP and
decreased Hb levels in 9, 1, 1, and 1 patient(s), respect-
ively. Thrombocytopenia was observed in 1 patient
(Table 5).

Moreover, CTCAE grade II or higher adverse reactions
were observed in 2 patients with increased CPK levels
(grade II and IV) and in 1 patient each with increased γ-
GTP levels, decreased Hb levels, and thrombocytopenia
(all were grade II). The adverse reactions reported by 24
patients were myalgia in 7, rash in 6, discomfort in 3,
and myospasm in 2 patients, as well as arrhythmia,
numbness, malaise, nausea, weakness, and vertigo in 1
patient each. Of these reported adverse reactions,
muscle-associated adverse reactions suggestive of
rhabdomyolysis (increased CPK levels, myalgia, myos-
pasm, numbness, malaise, and weakness) accounted for
a large proportion of the patients (21 out of 37).

Comparison with the reported adverse reactions to or-
ally administered Mevalotin® revealed no apparent in-
crease in the incidence of adverse reactions to orally
administered Maibastan® tablets (Table 6). Moreover, 3
cases of discomfort and 1 case of arrhythmia, which
were not reported as adverse reactions to Mevalotin®,
were examined in detail using the information in the
electronic medical records (e.g., past history and con-
comitant drugs).

Case 1 is a 48-year-old man treated for dyslipidemia
on an outpatient basis. Ten months after switching to
Maibastan® tablet, he complained of discomfort, and
drug treatment was discontinued. The patient's discom-
fort was related to the use of Maibastan® tablet together
with 2 drugs prescribed for sinusitis at another hospital
(unspecified). The other concomitant drugs used were
Bayaspirin® tablet (Bayer AG), Juvela® capsule (Eisai Co.,
Ltd.), and Foliamin® tablet (Takeda Pharmaceutical Co.,
Ltd.). Discontinuation of all drugs relieved the patient's
discomfort.

Case 2 is a 76-year-old man treated for chronic renal
failure, renal anemia, hypertension, prostatomegaly, and
dyslipidemia on an outpatient basis. Two months after
switching to Maibastan® tablet, he complained of dis-
comfort, and drug treatment was discontinued. Because
of discomfort, the patient discontinued the use of Uriel®
(Daiichi Sankyo Co. Ltd.), Maibastan®, Tenormin® (Astra-
Zeneca, Inc.), and Myslee® tablet (AstraZeneca, Inc.) at
his own discretion. The patient's discomfort was subse-
quently relieved. The use of the other concomitant
drugs, Adalat® (Bayer AG) and Blopress® tablet (Takeda
Pharmaceutical Co., Ltd.), was not discontinued.

Case 3 is an 88-year-old woman treated for hypothyroidism and dyslipidemia on an outpatient basis. Two months after switching to Maibastan® tablet, she complained of discomfort, and the use of the other concomitant drug, Thyradin-S® tablet (Takeda Pharmaceutical Co. Ltd.), was not discontinued.

Case 4 is a 66-year-old woman treated for diabetes mel-
litus, hypertension, and dyslipidemia on an outpatient

| Age (years) | Sex | Treatment duration (weeks) | Adverse reaction | CTCAE Grade |
|------------|-----|---------------------------|------------------|-------------|
| 70         | Female | 16 | Increased CPK 200 IU/L | I |
| 66         | Female | 10 | Increased CPK 219 IU/L | I |
| 67         | Female | 40 | Increased CPK 189 IU/L | I |
| 68         | Female | 15 | Increased CPK 200 IU/L | I |
| 78         | Female | 4  | Increased CPK 2898 IU/L | IV |
| 52         | Male   | 12 | Increased CPK 321 IU/L | I |
| 67         | Male   | 35 | Increased CPK 762 IU/L | I |
| 36         | Male   | 4  | Increased CPK 404 IU/L | I |
| 40         | Male   | 10 | Increased CPK 815 IU/L | II |
| 69         | Female | 4  | Increased AST 49 IU/L | I |
| 41         | Male   | 32 | Increased ALT 42 IU/L | I |
| 65         | Male   | 23 | Decreased Hb 9.7 g/dL | - |
| 85         | Female | 15 | Thrombocytopenia 65,000 /mL | II |

Aspartate aminotransferase, AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γ-GTP; alkaline phosphatase, ALP; hemoglobin, Hb; The Common Terminology Criteria for Adverse Events, CTCAE
basis. Twenty months after switching to Maibastan® tablet, she complained of a racing pulse, and treatment was dis-
continued. This patient discontinued Maibastan® tablet at
her own discretion and her symptom was subsequently re-
lieved. The use of the concomitant drugs Olmetec® (Daii-
chi Sankyo Co., Ltd.) and Fastic® tablet (Mochida
Pharmaceutical Co., Ltd.) was not discontinued (Table 7).

Discussion
Efficacy and safety assessment based on laboratory data
included those of the patients in the long-term use group,
which consisted of 556 patients in the long-term contin-
ued use and 39 patients in the treatment discontinuation
(long-term) group. Regarding the efficacy in the long-term
continued use group, no statistically significant difference
was observed between the first TC, TG, HDL-C, and
LDL-C levels measured during the short-term use of
Maibastan® tablets and those of the last measured during
the long-term treatment period. Furthermore, no significant
difference between these parameters was observed in the
treatment discontinuation group (long-term). Thus, it was
assumed that the effects of the long-term use of Maibastan®
tablets were similar to those of Mevalotin® tablets.
Similarly, regarding the safety assessment in the long-
term continued use group, no statistically significant dif-
ference was observed between the first AST, ALT, CPK,
γ-GTP, ALP, LDH, T-Bil, BUN, Scr, and HbA1c levels mea-
sured during the short-term use of Maibastan® tablet
period and those of the last measurement during the
long-term treatment period, except for the ALT levels.
While the ALT levels were significantly lower in the
Maibastan® tablet long-term use group than those in the
short-term use group, the levels did not fluctuate through-
out the long-term treatment period. A recent report from
the Greek Atorvastatin and Coronary Heart Disease
Evaluation (GREACE) study indicated that the use of
statins in patients with a fatty liver improved liver function
and reduced cardiovascular events [11]. As for the reason
for the decreased ALT levels, the report also suggested
that the inhibitory action of Maibastan® against hepatic
3-methylglutaryl coenzyme A (HMG-CoA) reductase

| Adverse reaction | Case (N) | Present study Incidence (%) | Package insert Incidence (%) |
|------------------|---------|----------------------------|----------------------------|
| Increased CPK    | 9       | 0.67                       | Unknown                    |
| Myalgia          | 7       | 0.52                       | Unknown                    |
| Rash             | 6       | 0.45                       | 0.1–1                      |
| Discomfort       | 3       | 0.22                       | No documentation          |
| Myospasm         | 2       | 0.15                       | <0.1                       |
| Arrhythmia       | 1       | 0.07                       | No documentation          |
| Increased ALP and γ-GTP | 1 | 0.07 | 0.1–1 |
| Numbness         | 1       | 0.07                       | <0.1                       |
| Malaise          | 1       | 0.07                       | <0.1                       |
| Nausea           | 1       | 0.07                       | <0.1                       |
| Increased AST and ALT | 1 | 0.07 | Unknown |
| Thrombocytopenia | 1       | 0.07                       | Unknown                    |
| Anemia (decreased Hb) | 1 | 0.07 | Unknown |
| Weakness         | 1       | 0.07                       | Unknown                    |
| Vertigo          | 1       | 0.07                       | Unknown                    |

Table 7: Cases of adverse reactions that have not been reported for the branded drug

| Adverse reaction | Course                                                                                      |
|------------------|--------------------------------------------------------------------------------------------|
| Discomfort       | A 48-year-old man complained of discomfort after receiving Maibastan® for 10 months, and the treatment was discontinued. Before symptom onset, the concomitant drugs had not been changed. Discontinuation of Maibastan® and the concomitant drugs* resulted in symptom relief.                                                                 |
|                  | *Bayaspirin®, Juvela®, Foliamin®, Erythrocin®, and Mucodyne*                                                                 |
|                  | A 76-year-old man complained of discomfort after receiving Maibastan® for 2 months, and the treatment was discontinued. Before symptom onset, the concomitant drugs* had not been changed. Discontinuation of Maibastan®, Urief®, Tenormin®, and Myslee* resulted in symptom relief.                                                                 |
|                  | *Urief®, Tenormin®, Myslee®, Adalat®, and Biopress*                                                                 |
|                  | An 88-year-old woman complained of discomfort after receiving Maibastan® for 2 months, and drug treatment was changed to Epader®. Before symptom onset, the concomitant drugs* had not been changed. Discontinuation of Maibastan® and Hachimi-jio-gan® resulted in symptom relief.                                                                 |
|                  | *Thyradin S® and Hachimi-jio-gan®*                                                                 |
| Arrhythmia       | A 66-year-old woman complained of the sensation of having a racing pulse after receiving Maibastan® for 20 months, and the treatment was discontinued. Before symptom onset, the concomitant drugs* had not been changed. Discontinuation of Maibastan® resulted in symptom relief.                                                                 |
|                  | *Olmetec® and Fastic®*                                                                 |

Creatine phosphokinase, CPK; gamma-glutamyl transferase, γ-GTP; alkaline phosphatase, ALP; aspartate aminotransferase, AST; alanine aminotransferase, ALT; hemoglobin, Hb

Table 6: Comparison of adverse reactions reported for the branded and generic drugs

| Adverse reaction | Present study Incidence (%) | Package insert Incidence (%) |
|------------------|----------------------------|----------------------------|
| Increased CPK    | 0.67                       | Unknown                    |
| Myalgia          | 0.52                       | Unknown                    |
| Rash             | 0.45                       | 0.1–1                      |
| Discomfort       | 0.22                       | No documentation          |
| Myospasm         | 0.15                       | <0.1                       |
| Arrhythmia       | 0.07                       | No documentation          |
| Increased ALP and γ-GTP | 0.07 | 0.1–1 |
| Numbness         | 0.07                       | <0.1                       |
| Malaise          | 0.07                       | <0.1                       |
| Nausea           | 0.07                       | <0.1                       |
| Increased AST and ALT | 0.07 | Unknown |
| Thrombocytopenia | 0.07                       | Unknown                    |
| Anemia (decreased Hb) | 0.07 | Unknown |
| Weakness         | 0.07                       | Unknown                    |
| Vertigo          | 0.07                       | Unknown                    |

Suzuki et al. Journal of Pharmaceutical Health Care and Sciences (2016) 2:1 Page 7 of 9
reduced stress, such as a fatty liver, affecting liver function. A similar comparison of the laboratory parameter values in the treatment discontinuation group showed no significant differences.

For the safety assessment, review of the patients’ medical records identified the reasons underlying all cases of drug discontinuation and change during the current study period. Detailed review of the medical records containing no documented reasons revealed the absence of patients’ complaints about symptoms suggestive of adverse reactions, abnormal laboratory data during treatment, or adverse events, such as death.

Next, to investigate the safety of the long-term use of Maibastan® tablets, the medical records of patients who had died or had adverse reactions were reviewed in detail. Among all the 36 patients who had died, drug discontinuation and change were suspected to be caused by primary diseases, and it was assumed that there was no causal relationship with the oral administration of Maibastan® tablets. In the drug discontinuation and change due to adverse reactions cases, Maibastan® tablet was considered responsible for each adverse reaction. Indeed, 21 out of the 37 cases showed muscle-associated symptoms suggestive of rhabdomyolysis (increased CPK levels, myalgia, myospasm, numbness, malaise, and weakness). However, these findings were derived from pravastatin sodium preparations and may be considered Maibastan® tablet-unrelated adverse reactions. Moreover, the adverse reactions observed in 12 out of the 37 cases, which included rash, increased ALP and γ-GTP levels, nausea, hepatopathy, thrombocytopenia, decreased Hb levels, and vertigo, were also reported for the branded drug (Mevalotin®), and no apparent increase in their incidence was observed. Thus, these adverse reactions may also be considered Maibastan® tablet-unrelated. Because discomfort (case 1, 2, and 3) and arrhythmia (case 4), which were observed in the remaining 4 cases, had not been reported in the adverse reaction reports for the branded drug, we investigated whether these adverse reactions were specific to Maibastan® tablet treatment. Although discomfort was relieved in these 3 cases (case 1, 2, and 3) after discontinuation of Maibastan® tablet, this adverse reaction may not be specific to the tablet: the patients were taking several oral drugs and had comorbidities associated with poor physical conditions, such as sinusitis, renal anemia, and hypothyroidism. Although the symptom (case 4) was relieved after discontinuation of Maibastan® tablet only, it has been reported that arrhythmic symptoms, such as extrasystole, are detected in approximately 3.8% of healthy people, and that the incidence of such symptoms is higher in patients with hypertension [12, 13]. Because the patient of case 4 had concomitant hypertension, it cannot be ruled out that the racing pulse she experienced was caused by transient extrasystole. Thus, this symptom may not be a Maibastan® tablet-specific adverse reaction. According to the findings described above, it is assumed that Maibastan® tablet may be safely used for long-term treatment.

We previously conducted questionnaire surveys on generic drugs among doctors, nurses, and pharmacists at our hospital and found that several healthcare professionals had concerns about the limited amount of information on clinical efficacy and adverse reactions [14, 15]. Although several studies have examined the efficacy and safety of generic drugs, the number of studies focusing on individual drugs and the amount of information provided by such studies has not been sufficient to eliminate this concern. Some studies have also assessed the efficacy and safety of generic pravastatin sodium tablets. However, in several of these studies, less than 100 cases were evaluated, and the duration of generic drug treatment lasted for 3 months or less; even the longest duration lasted 6 months at most [16–19]. Drugs for the treatment of chronic diseases are often orally administered for many years. Especially, for dyslipidemia, strict long-term lipid control is necessary for the primary and secondary prevention of cardiovascular events. Thus, studies on the efficacy and safety of long-term drug use are highly useful information sources. The present study provides results on the efficacy and safety of a generic drug based on the assessment of a sufficient number of cases and sufficient treatment duration. The proliferation of generic drugs is highly desired to reduce healthcare spending. However, the major future tasks are not only to ensure their bioequivalence with branded drugs, but also to increase data provision on generic drug efficacy and safety by conducting clinical studies. In these tasks, pharmacists are essential since they are drug specialists. Therefore, pharmacists should be actively involved through pharmacist-led clinical assessments of generic drugs. The present study may have large clinical significance for the efficacy and safety assessment of the long-term use of generic drugs.

Conclusion
This study shows that the long-term use of generic pravastatin sodium is effective and safe, and may help dispel the concerns about generic drugs.

Competing interests
The authors declare that they have no conflicts of interest.

Authors’ contributions
All authors conceived the study, MS, MK carried out the acquisition of patient data and designed the study and analyses. All authors read and approved the final manuscript.

Acknowledgements
We would like to appreciate TOWA Pharmaceutical Co., Ltd for advices about statistical analysis.

Author details
1 Department of Pharmacy, Kameda General Hospital, 929 Higashi-cho, Kamogawa-City 296-8602 Chiba, Japan. 2 Postgraduate Education Center,
Chimori S, Mimori S, Mimori Y, Shinohara T, Tateyama M. Variation in serum lipid level with the change from pravastatin to generic drug in high blood cholesterol patients with diabetes. Ther Res. 2006;27:2271–4.

18. Tanabe K, Takeuchi M, Ikezaki T, Kitazawa H, Toyomoto T, Nakabayashi T. Assessment of therapeutic equivalence of original and generic preparations of pravastatin sodium (MevalotinTM vs. MevanTM): A retrospective study. Jpn J Pharm Health Care Sci. 2008;34:57–4.

19. Kikikawa Y, Iwaki S, Ito M, Ishikura K, Ikeda K, Sato K, et al. Comparative clinical evaluation of the efficacy and safety between the original drug and generic products (II). Jap J Drug Inform. 2011;13:88–94.

Received: 17 July 2015 Accepted: 22 November 2015

Published online: 18 December 2015

References

1. Ikeda S. Generic drugs and measures to control healthcare spending (in Japanese). J Ther. 2007;89:521–5.

2. Okubo T, Okubo N. A survey of pharmacists in the Department of Pharmacy at Vanderbilt University Medical Center in Tennessee, the United States (in Japanese). J Pract Pharm. 2005;56:113–9.

3. Ministry of Health, Labour and Welfare. Reduction in costs of drugs for Japanese citizens: explanatory material. http://www.cas.go.jp/p/seisaku/gyoukaku/h26_fall/pdf/ronen/03koureoutoumei.pdf (12 Nov 2014). Accessed 18 May 2015.

4. Ministry of Health, Labour and Welfare. Roadmap for further promotion of the use of generic drugs. http://www.mhlw.go.jp/stf/houdou/2r9852000002z7it.pdf (5 Apr 2013). Accessed 18 May 2015.

5. Miura S, Ishida T, Nakagami M, Yamaoka K. A questionnaire survey of the current status of use of generic products. J Jpn Soc Hosp Pharm. 2008;44:719–22.

6. Suzuki M, Onishi M, Morisaki K, Nakazaki M, Kawana M, Nagai J, et al. Assessment of efficacy and safety of branded and generic versions of pravastatin sodium based on laboratory data: A retrospective analysis. Jpn J Pharm Health Care Sci. 2011;37:449–55.

7. Terada D, Sugiyama E, Nagamoto T, Miyao M. Effects of long-term administration with generic benzbromarone on serum uric acid level and liver function in hyperuricemia patients. Jpn J Gener. Med. 2011;5:22–6.

8. Terada D, Ashida T, Nagamoto T, Miyao M. Effects of generic "benzbromarone" on liver function of patients with hyperuricemia—changes by age and dose. Pharmacometrics. 2013;84:63–6.

9. Hori S, Onishi E, Suda Y, Iwasaki J, Mizuoka D, Tsuchishita Y, et al. Comparison of biokinetics following the long-term oral administration of generic amiodarone and safety (in Japanese). Jpn J Pharm Assoc. 2013;65:1087–9.

10. Goto Y, Yamamoto A, Goto Y, Yoshida S, Saito Y, Oshima K, et al. Study on clinical efficacy of CS-514 (pravastatin) in long-term treatment on hypercholesterolemia. J Clin Therap Med. 1988;4:409–37.

11. Athyros V, Tzoumalos K, Gossios TD, Griva T, Anagnostis P, Karagiannis T, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet. 2010;376:1916–22.

12. Engel G, Cho S, Ghayoumi A, Yamazaki T, Chun S, Fearon WF, et al. Prognostic significance of PVCs and resting heart rate. Ann Noninvasive Electrocardiol. 2007;12:121–3.

13. Simpson Jr RJ, Cascio WE, Schreiner PJ, Crow RS, Rautaharju PM, Heiss G. Prevalence of premature ventricular contractions in a population of African American and white men and women: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2002;143:55–40.

14. Suzuki M, Wong PC, Nagai J, Sasaki T. Identification of problems associated with nursing duties when generic drugs are introduced and measures against the problems (in Japanese). Annual meeting of Japanese society of pharmaceutical health care and science. 2007, 270.

15. Suzuki M, Wong PC, Nagai J, Sasaki T. Questionnaire survey on generic drugs: differences between doctors and pharmacists (in Japanese). Annual meeting of Japanese society of pharmaceutical health care and science. 2008, 307.

16. Hirano T. Fluctuations in serum lipid levels after switching from branded to generic pravastatin sodium (in Japanese). Prog Med. 2005;25:2415–7.

17. Chimori S, Mimori S, Mimori Y, Shinohara T, Tateyama M. Variations in serum lipid level with the change from pravastatin to generic drug in high blood cholesterol patients with diabetes. Ther Res. 2006;27:2271–4.